An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use

BMC Clinical Pharmacology

Volumn 2, Issue , 2002, Pages

  Ward, Alexandra ^a   Caro, J Jaime ^a,b   Green, Traci Craig ^a   Huybrechts, Krista ^a   Arana, Alejandro ^c   Wait, Suzanne ^d,f   Eleftheriou, Androulla ^e  

^a CARO RESEARCH INSTITUTE   (United States)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c Novartis Pharmaceutica   (Spain)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Thalassemia International Foundation   (Cyprus)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; IRON CHELATING AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; CYPRUS; DOSE RESPONSE; EGYPT; FEMALE; GREECE; HEALTH CARE DELIVERY; HEALTH SURVEY; HONG KONG; HUMAN; INDIA; IRAN; ITALY; JORDAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; SCHOOL CHILD; SIDE EFFECT; TAIWAN; THALASSEMIA MAJOR; UNITED STATES; BETA THALASSEMIA; CHELATION THERAPY; CLINICAL TRIAL; HEALTH CARE SURVEY; MULTICENTER STUDY; PATIENT COMPLIANCE; QUALITY OF LIFE;

BETA-THALASSEMIA; CHELATION THERAPY; DEFEROXAMINE; HEALTH CARE SURVEYS; HUMANS; IRON CHELATING AGENTS; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 0012127970     PISSN: 14726904     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-2-3     Document Type: Article

References (30)

1. Modell B, ed: Guidelines for the control of haemoglobin disorders. World Health Organization 1994
2. Cao A, Gabutti V, Galanello R, Masera G, Modell B, Di Palma A, Piga A, Vullo C, Wonke B: Management protocol for the treatment of thalassemia patients. Thalassemia International Federation. Nicosia, Cyprus 1997
3. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR: Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994, 331:574-578
4. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S: Survival and causes of death in thalassemia major. Lancet 1989, 2:27-30
5. Blowey DL, Hebert D, Arbus GS, Pool R, Korus M, Koren G: Compliance with cyclosporine in adolescent renal transplant recipients. Pediatr Nephrol 1997, 11:547-551
6. Phipps S, DeCuir-Whalley S: Adherence issues in pediatric bone marrow transplantation. J Pediatr Psychol 1990, 15:459-475
7. Pidgeon V: Compliance with chronic illness regimens: school aged children and adolescents. J Pediatr Nurs 1989, 4:36-47
8. Brittenham G, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994, 331:567-573
9. Gabutti V, Piga A: Results of long term iron chelating therapy. Acta Haematol 1996, 95:26-36
10. Olivieri NF: The beta-thalassemias. N Engl J Med 1999, 341:99-109
11. Hussain MA, Green N, Flynn DM, Hussein S, Hoffbrand AV: Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet 1976, 2:1278-1280
12. Modell B, Letsky EA, Flynn DM, Peto R, Weatherall DJ: Survival and desferrioxamine in thalassemia major. BMJ 1982, 284:1081-1084
13. Ehlers KH, Levin AR, Markenson AL, Marcus JR, Klein AA, Hilgartner MW, Engle MA: Longitudinal study of cardiac function in thalassemia major. Ann N Y Acad Sci 1980, 344:397-404
14. Cromer B, Tarnowski KJ: Non-compliance in adolescents: a review. J Dev Behav Pediatr 1989, 10:207-215
15. Beratis S: Noncompliance with iron chelation therapy in patients with beta thalassaemia. J Psychosom Res 1989, 33:739-745
16. McGee A, Koren G, Liu P, Freedman M, Rose V, Benson L, Olivieri N: Cardiac disease-free survival in patients with thalassemia major treated with subcutaneous deferoxamine: an update of the Toronto cohort. Blood 1989, 74:311a Abstract 1172
17. Olivieri N: Randomized trial of deferiprone (L1) and deferoxamine (DFO) in thalassemia major. Blood 1996, 88(suppl 1):651a Abstract 2593
18. Modell B, Khan M, Darlison M: Survival in beta-thalassemia major in the UK: data form the UK Thalassemia Register. Lancet 2000, 355:2051-2052
19. Rees L: Compliance with growth hormone therapy in chronic renal failure and post transplant. Pediatr Nephrol 1997, 11:752-754
20. Wolff G, Strecker K, Vester U, Latta K, Ehrich JH: Non-compliance following renal transplantation in children and adolescents. Pediatr Nephrol 1998, 12:703-708
21. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD: Persistence with treatment for hypertension in actual practice. Can Med Assoc J 1999, 160:31-37
22. Bush S, Mandel FS, Giardina PJ: Future orientation and life expectations of adolescents and young adults with thalassemia major. Ann N Y Acad Sci 1998, 850:361-369
23. Goldbeck L, Baving A, Kohne E: Psychosocial aspects of beta-thalassemia: distress, coping and adherence. Klin Padiatr 2000, 212:254-259
24. Sherman M, Koch D, Giardina P, Hymowitz P, Siegel R, Shapiro T: Thalassemic children's understanding of illness: a study of cognitive and emotional factors. Ann N Y Acad Sci 1985, 445:327-336
25. Yamashita R, Foote D, Weissman L: Patient cultures: thalassemia service delivery and patient compliance. Ann N Y Acad Sci 1998, 850:521-552
26. Rosenstock IM: The health belief model: explaining health behavior through expectancies. In: Health Behavior and Health Education (Edited by: Ganz K) New York, Jossey-Bass 1989, 39-62
27. Willey C, Redding C, Stafford J, Garfield F, Geletko S, Flanigan T, Melbourne K, Mitty J, Caro JJ: Stages of change for adherence with medication regimens for chronic diseases: development and validation of a measure. Clin Ther 2000, 22:853-871
28. Koch DA, Giardina PJ, Ryan M, MacQueen M, Hilgartner MW: Behavioral contracting to improve adherence in patients with thalassemia. J Pediatr Nurs 1993, 8:106-111
29. Loukopoulos D: Current status of thalassemia and the sickle cell syndromes in Greece. Semin Hematol 1996, 33:76-86
30. Pearson HA, Guiliotis DK, Rink L, Wells JA: Patient age distribution in thalassemia major: changes from 1973 to 1985. Pediatrics 1987, 80:53-57